You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

 

Online download statistics by month:

Online download statistics by month: November 2020 to March 2026

AbstractFullPdf
Nov 2020281281406
Dec 2020283283235
Jan 202123823889
Feb 202120220251
Mar 202111411449
Apr 202116716765
May 202113413447
Jun 202127627652
Jul 202112212243
Aug 202111811858
Sep 202113213263
Oct 202113113183
Nov 2021131129100
Dec 2021818763
Jan 2022848775
Feb 2022738472
Mar 202229730874
Apr 2022919543
May 202218619468
Jun 202233634686
Jul 202217918254
Aug 202214715147
Sep 202211912549
Oct 202221122456
Nov 202223123347
Dec 202211311533
Jan 202312913135
Feb 202313113132
Mar 202318118871
Apr 202311711835
May 202322122154
Jun 202314214331
Jul 202312713131
Aug 202310010224
Sep 2023989915
Oct 202311311316
Nov 202312512623
Dec 202310710723
Jan 2024474817
Feb 202412812824
Mar 202410910932
Apr 202411711753
May 2024818227
Jun 2024727132
Jul 202428829225
Aug 202410310328
Sep 202410010027
Oct 2024929334
Nov 2024959634
Dec 2024889525
Jan 2025737337
Feb 2025656572
Mar 2025636430
Apr 2025646529
May 2025717137
Jun 2025676829
Jul 2025110
Aug 2025110
Oct 2025110
Mar 2026110
Total779579123090